Thanks for the info. However, it still does not address my concern over
how to reliably form the arm of the study which is to include 'early stage
Alzheimers'. Since the diagnostic paradigm currently is a complex and
a subjectively administered assessment by a physician and the CT, PET, and MRI scans are not definitive, especially in early stage, i.e Amyvid and there
is no concrete association of TAU tangles with Alzheimers, then how can you
be sure that you have actually enrolled Early Stage patients in the Lympro
Trial being put together.